Tenax Therapeutics, Inc.

NasdaqCM:TENX Voorraadrapport

Marktkapitalisatie: US$15.3m

Tenax Therapeutics Beheer

Beheer criteriumcontroles 4/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Chris Giordano

Algemeen directeur

US$644.8k

Totale compensatie

Percentage CEO-salaris62.9%
Dienstverband CEO3.3yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn3.3yrs
Gemiddelde ambtstermijn bestuur3.8yrs

Recente managementupdates

Recent updates

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Sep 15

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

Jan 20
Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

Analyse CEO-vergoeding

Hoe is Chris Giordano's beloning veranderd ten opzichte van Tenax Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$13m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$645kUS$405k

-US$8m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$8m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$667kUS$386k

-US$11m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$11m

Dec 31 2021US$861kUS$183k

-US$32m

Compensatie versus markt: Chris's total compensation ($USD644.77K) is about average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Giordano (50 yo)

3.3yrs

Tenure

US$644,770

Compensatie

Mr. Christopher T. Giordano, also known as Chris, has been the Chief Executive Officer and Director of Tenax Therapeutics, Inc. since joining on July 14, 2021 and serves as its President since October 29,...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Christopher Giordano
CEO, President & Director3.3yrsUS$644.77kgeen gegevens
Stuart Rich
Chief Medical Officer & Director3.8yrsUS$481.22k0.043%
$ 6.5k
Lawrence Hoffman
Interim Chief Financial Officerless than a yeargeen gegevensgeen gegevens
Doug Randall
Executive Vice President of Commercial & Business Operationsno datageen gegevensgeen gegevens
Douglas Hay
Senior Vice President of Regulatory Affairsno datageen gegevensgeen gegevens

3.3yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren management: TENX's management team is considered experienced (3.3 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Christopher Giordano
CEO, President & Director3.3yrsUS$644.77kgeen gegevens
Stuart Rich
Chief Medical Officer & Director3.8yrsUS$481.22k0.043%
$ 6.5k
Gerald Proehl
Independent Chairman10.6yrsUS$88.50k0.049%
$ 7.5k
Michael Davidson
Independent Director3.8yrsUS$57.50k0.085%
$ 12.9k
Daniel Burkhoff
Member of PH-Left Heart Disease Scientific Advisory Board6.8yrsgeen gegevensgeen gegevens
Declan Doogan
Independent Director3.8yrsUS$48.50k0.067%
$ 10.2k
Robyn Hunter
Independent Director2.8yrsUS$65.00k0%
$ 0
June Almenoff
Independent Director3.8yrsUS$59.50k0%
$ 0
Sanjiv Shah
Member of PH-Left Heart Disease Scientific Advisory Board6.8yrsgeen gegevensgeen gegevens
Barry Borlaug
Member of PH-Left Heart Disease Scientific Advisory Board4.8yrsgeen gegevensgeen gegevens
Robert Frantz
Member of PAH Scientific Advisory Boardno datageen gegevensgeen gegevens
Anna Hemnes
Member of PAH Scientific Advisory Boardno datageen gegevensgeen gegevens

3.8yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: TENX's board of directors are considered experienced (3.8 years average tenure).